[의학신문·일간보사=김영주 기자]The possibility of developing an innovative new drug that can dramatically improve the quality of life of patients with short bowel syndrome, an intractable and rare disease that causes malabsorption and malnutrition due to loss of more than 60% of small intestine (small intestine) function congenitally or postnatally due to surgical resection Confirmed.
Hanmi Pharm (CEO Kwon Se-chang and Woo Jong-su) presented oral and oral presentations of the research results of LAPSGLP-2 Analog, a new biologic drug for treating short bowel syndrome, at the European Society for Clinical Nutrition and Metabolism (ESPEN) held online from the 9th to the 14th. It was announced on the 13th that it was announced as a poster and received attention.
LAPSGLP-2 Analog is a long-acting biopharmaceutical to which Hanmi Pharm’s proprietary platform technology, Labscovery, is applied. It is an innovative treatment developed to be administered ‘once a month’ for the first time in the world through its durability and excellent villous cell growth promoting effect. It was designated as an orphan drug by the US FDA and European EMA in 2019, and as a pediatric orphan drug (RPD) and fast-track development drug by the FDA in 2020 and 2021.
According to the results of the study published this time, the growth and absorption of the small intestine in the group administered with LAPSGLP-2 Analog once a month compared to the model taking the only treatment for short bowel syndrome that needs to be administered daily or the once-weekly long-acting treatment currently being developed. ability was found to increase. In addition, when the existing treatment was administered daily, then switched to LAPSGLP-2 Analog and administered once a month, even better efficacy was shown.
Short bowel syndrome occurs in about 24.5 out of 100,000 newborns, severely affecting the growth of children and adolescents, and the survival rate is also very low, less than 50%. Artificial nutrition supplementation such as total intravenous nutrition (a method of supplying nutrients through vena cava or peripheral blood vessels) for growth and maintenance of life is required for a long period of time, which greatly affects the quality of life of patients.
Se-chang Kwon, president of Hanmi Pharm, said, “I am delighted to see the possibility that LAPSGLP-2 Analog can provide better treatment options than existing treatments. We will do our best to advance it,” he said.
.
